A compound with low toxicity and pronounced antidepressant activity upon single and long-term administration was discovered by us earlier among a series of new thietanylxanthine derivatives. The present article focused on the central mechanisms of action of 2-[3-methyl-7-(thietan-3-yl)-1-ethylxanth-7-ylthio]acetic acid hydrazide (laboratory code M-20). Neuropharmacological analysis showed that M-20 at doses of 0.97 and 12 mg/kg exhibited effects indicative of possible stimulatory action on adrenergic and inhibitory action on GABA-ergic neurotransmission in brains of outbred white mice. M-20 at a dose of 12 mg/kg produced an activating effect on the serotoninergic system in addition to action on the adrenergic and GABA-ergic systems and altered the activity of the cholinergic system. M-20 at doses of 0.97 and 12 mg/kg did not alter the effects of haloperidol and L-DOPA, which indicated that it did not influence dopaminergic neurotransmission and MAO-inhibiting activity. The results indicated that M-20 was promising (at the low dose) for use with depression associated with decreased activity of the serotoninergic system without side effects on the dopaminergic and cholinergic systems.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-020-02218-7/MediaObjects/11094_2020_2218_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-020-02218-7/MediaObjects/11094_2020_2218_Fig2_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-020-02218-7/MediaObjects/11094_2020_2218_Fig3_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-020-02218-7/MediaObjects/11094_2020_2218_Fig4_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11094-020-02218-7/MediaObjects/11094_2020_2218_Fig5_HTML.jpg)
Similar content being viewed by others
References
V. A. Golovacheva and V. A. Parfenov, Med. Sovet, No. 5, 55 – 60 (2015); doi: https://doi.org/10.21518/2079-701X-2015-5-55-61.
Depression and Other Common Mental Disorders; Global Health Estimates, World Health Organization, Geneva (2017).
K. S. Raevskii, Psikhiatr. Psikhofarmakoter., 3(5), 162 – 166 (2001).
L. A. Levchuk, S. A. Ivanova, E. V. Gutkevich, et al., Sib. Vestn. Psikhiatr. Narkol., 69(6), 13 – 16 (2011).
N. L. Shimanovskii, M. A. Epinetov, and M. Ya. Mel?nikov, Molecular and Nanopharmacology [in Russian], Fizmatlit, Moscow (2009).
G. G. Davlyatova and L. A. Valeeva, Zdorov. Obraz. XXI Veke, 18(7), 132 – 135 (2016).
L. A. Valeeva, G. G. Davlyatova, Yu. V. Shabalina, et al., Khim.-farm. Zh., 50(6), 8 – 11 (2016); doi: https://doi.org/10.30906/0023-1134-2016-50-6-8-11.
F. A. Khaliullin, I. L. Nikitina, E. E. Klen, et al., Khim.-farm. Zh., 53(12), 8 – 15 (2019); doi: https://doi.org/10.30906/0023-1134-2019-53-12-8-15.
Yu. V. Shabalina, F. A. Khaliullin, I. L. Nikitina, et al., Khim.-farm. Zh., 53(11), 21 – 24 (2019); doi: https://doi.org/10.30906/0023-1134-2019-53-11-21-24.
D. Z. Murataev, Yu. V. Shabalina, and F. A. Khaliullin, Bashkir. Khim. Zh., 19(1), 220 – 222 (2012).
A. N. Mironov, Handbook for Preclinical Drug Trials [in Russian], Grif i K, Moscow (2012).
R. U. Khabriev, Handbook for Experimental (Preclinical) Studies of New Drugs [in Russian], Meditsina, Moscow (2005).
S. Glantz, Primer of Biostatistics, 4th Ed., McGraw-Hill Inc., New York (1997), 473 pp.
A. Bielenica, E. Kedzierska, M. Kolinski, et al., Eur. J. Med. Chem., 116, 173 – 186 (2016); doi: https://doi.org/10.1016/j.ejmech.2016.03.073.
J. Arnt, J. Hyttel, and J. J. Larsen, Acta Pharmacol. Toxicol., 55(5), 363 – 372 (1984); doi: https://doi.org/10.1111/j.1600-0773.1984.tb01996.x.
F. García-Oscos, O. Torres-Ramírez, L. Dinh, et al., Synapse, 69(3), 115 – 127 (2015); https://doi.org/10.1002/syn.21794.
S. Koyama, C. Kubo, J.-S. Rhee, et al., J. Physiol., 518(2), 525 – 538 (1999); doi: https://doi.org/10.1111/j.1469-7793.1999.0525p.x.
A. O. Korolev, T. S. Kalinina, A. V. Volkova, et al., Eksp. Klin. Farmakol., 77(16), 3 – 7 (2014).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 54, No. 5, pp. 7 – 10, May, 2020.
Rights and permissions
About this article
Cite this article
Valeeva, L.A., Davlyatova, G.G. & Shimanovskii, N.L. Neuropharmacological Analysis of the Antidepressant Action of 2-[3-Methyl-7-(Thietan-3-Yl)-1-Ethylxanth-8-YLTHIO] Acetic Acid Hydrazide. Pharm Chem J 54, 435–438 (2020). https://doi.org/10.1007/s11094-020-02218-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-020-02218-7